← Back to all trials
Not Yet Recruiting
NCT05630768
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
Conditions: Postmenopausal Osteoporosis
Sex: Female
Ages: 50 Years – 80 Years
Phase: PHASE4
Enrollment: 155
Sponsor: Dong-A ST Co., Ltd.
Location: Korea, Republic of
Summary
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
Eligibility Criteria
Main Inclusion Criteria:Postmenopausal womenPatients diagnosed with postmenopausal osteoporosis and administered denosumab for 1 yearMain Exclusion Criteria:Any contraindication to risedronateThose evaluated as inappropriate at the discretion of the investigator
Source: ClinicalTrials.gov (NCT05630768). StuddyBuddy aggregates publicly available trial information.
